# CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov

Source: https://onco.cc/trials/nct07322094/  
OnCo record `nct07322094` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer, run by TORL Biotherapeutics, LLC, now recruiting.

## Summary

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer is a phase 1/2 interventional study registered as NCT07322094 by TORL Biotherapeutics, LLC, with 60 participants planned, started 2025-12-10 and due to reach its primary completion in 2027-12. Interventions recorded: TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin. Conditions listed: FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07322094
- Phase: 1/2
- Setting: CATALINA-4: Phase 1B/2 Study of TORL-1-23 With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Newly Diagnosed Patients With Advanced Stage Ovarian Cancer
- Sponsor: TORL Biotherapeutics, LLC
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07322094: https://clinicaltrials.gov/study/NCT07322094

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)

---
JSON: https://onco.cc/api/v1/entities/nct07322094.json